Top Page
Acotec Scientific Holdings Limited
(Frankfurt:6669)
Acotec Scientific Holdings Limited (6669) vs. iShares MSCI Hong Kong ETF (EWH)
Acotec Scientific Holdings Limited Business Overview & Revenue Model
Acotec Scientific Holdings Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 523.12M | 533.99M | 473.85M | 395.55M | 303.81M | 193.97M |
| Gross Profit | 399.51M | 402.72M | 377.42M | 336.35M | 265.94M | 163.78M |
| EBITDA | 35.01M | 112.48M | 70.54M | 91.17M | -51.02M | -24.66M |
| Net Income | 32.08M | 52.28M | 14.49M | 70.14M | -79.08M | -44.29M |
Balance Sheet | ||||||
| Total Assets | 1.71B | 1.66B | 1.61B | 1.41B | 1.31B | 272.94M |
| Cash, Cash Equivalents and Short-Term Investments | 927.21M | 809.57M | 879.21M | 986.46M | 1.14B | 147.10M |
| Total Debt | 259.67M | 202.92M | 234.00M | 47.78M | 24.57M | 41.41M |
| Total Liabilities | 371.93M | 312.76M | 314.53M | 134.46M | 100.17M | 553.95M |
| Stockholders Equity | 1.34B | 1.35B | 1.30B | 1.28B | 1.21B | -281.01M |
Cash Flow | ||||||
| Free Cash Flow | -54.90M | 5.31M | -92.54M | -115.45M | -31.72M | -27.39M |
| Operating Cash Flow | 27.34M | 102.79M | -12.88M | -68.75M | -10.48M | -8.77M |
| Investing Cash Flow | -300.33M | 45.02M | -319.22M | -49.17M | -20.48M | -17.73M |
| Financing Cash Flow | 17.53M | -35.24M | -23.21M | -32.87M | 1.02B | 142.52M |
Acotec Scientific Holdings Limited Technical Analysis
Acotec Scientific Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$2.70B | 46.71 | 3.90% | ― | 10.44% | 238.85% | |
60 Neutral | HK$1.46B | ― | -1.28% | ― | 17.45% | 85.71% | |
56 Neutral | $3.16B | 5.05 | -5.68% | 5.76% | 8.05% | -41.83% | |
51 Neutral | €4.27B | ― | -10.43% | ― | 36.76% | 42.89% | |
50 Neutral | HK$1.16B | ― | -27.82% | ― | -6.12% | 0.43% | |
47 Neutral | HK$2.12B | ― | -2.19% | ― | 5.32% | 89.43% |
Acotec Scientific Holdings Limited Corporate Events
Acotec Scientific Holdings Limited announced that all resolutions proposed at its Annual General Meeting (AGM) held on June 30, 2025, were successfully passed by shareholders through a poll. The resolutions included the adoption of the company’s audited financial statements for 2024, the re-election of certain directors, and the re-appointment of KPMG as auditors. This successful AGM indicates strong shareholder support and stability in the company’s governance, potentially reinforcing its market position and stakeholder confidence.
Acotec Scientific Holdings Limited has outlined the terms of reference for its Nomination Committee, established to identify and recommend suitable candidates for the company’s board of directors. The committee, consisting mainly of independent non-executive directors, will ensure the selection process aligns with applicable laws and regulations, potentially impacting the company’s governance and strategic direction.
Acotec Scientific Holdings Limited has received approval from the PRC National Medical Products Administration for its Peripheral High-pressure Balloon Dilation Catheter, Armoni-HP®. This product is designed for use in percutaneous transluminal angioplasty in peripheral blood vessels and post-stent dilation, offering a high-strength fiber-composite design to ensure optimal clinical performance. The approval marks a significant step in the company’s product development, potentially enhancing its market position in the PRC healthcare sector.
Acotec Scientific Holdings Limited, a company incorporated in the Cayman Islands, has announced its annual general meeting scheduled for June 30, 2025, in Beijing. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements for 2024, the re-election of directors, and the re-appointment of KPMG as auditors. Additionally, the board will seek approval to allot and issue additional shares and securities, which could impact the company’s capital structure and shareholder value.
Acotec Scientific Holdings Limited announced that it has received approval from the PRC National Medical Products Administration for its Vertebral Artery Paclitaxel-coated Balloon Dilatation Catheter, AcoArt Verbena®. This product is designed for percutaneous transluminal angioplasty in patients with significant vertebral artery stenosis. Clinical trials have shown its efficacy and safety, with a notable reduction in restenosis rates compared to control groups. This approval marks a significant advancement in the treatment of vertebral artery stenosis, potentially reducing the risk of stroke. The company plans to initiate marketing activities in the PRC market, although successful commercialization is not guaranteed.
Acotec Scientific Holdings Limited announced that it has received registration approval from the PRC National Medical Products Administration for its Peripheral Thrombus Separation Stent. This device is designed to enhance the efficiency of vascular interventional procedures by facilitating the removal of obstructive embolic materials, thus reducing procedural complexity and time. The company plans to initiate marketing activities in the PRC market when appropriate, although there is no guarantee of successful market penetration.
Acotec Scientific Holdings Limited announced that it has received approval from the PRC National Medical Products Administration for its new product, the E-Peridge® Peripheral Scoring Balloon Dilatation Catheter. This device is designed to aid in the pre-dilation of stenotic lesions in peripheral vessels, enhancing vessel preparation for subsequent treatments. The approval marks a significant step in Acotec’s product development and market expansion efforts in China, although the company cautions that successful marketing of the product is not guaranteed.
Acotec Scientific Holdings Limited announced the approval of its Intelligent Aspiration Sensing Connector by the Beijing Municipal Medical Products Administration. This device, designed to enhance the efficiency of thrombus aspiration procedures through artificial intelligence, is expected to strengthen Acotec’s position in the peripheral thrombus treatment market. The company plans to initiate marketing activities in the PRC market, although successful commercialization is not guaranteed.